<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03819101</url>
  </required_header>
  <id_info>
    <org_study_id>2017-004639-35</org_study_id>
    <secondary_id>2017/2601</secondary_id>
    <nct_id>NCT03819101</nct_id>
  </id_info>
  <brief_title>Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer</brief_title>
  <acronym>PEACE-4</acronym>
  <official_title>A Phase III Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 2x2 factorial randomized, multicenter, international, open phase III trial.&#xD;
&#xD;
      The primary objective is to evaluate the benefit of acetylsalicylic acid and atorvastatin on&#xD;
      overall survival (OS) (main endpoint) for patients with castrate-resistant prostate cancer&#xD;
      starting first line treatment for CRPC&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 6, 2019</start_date>
  <completion_date type="Anticipated">March 2038</completion_date>
  <primary_completion_date type="Anticipated">March 2034</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>This is a 2x2 factorial randomized, multicenter, international, open phase III trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>OS will be calculated from the date of randomization to the date of death up to 15 years</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1210</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of Care (SOC) for CRPC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SOC + acetylsalicylic acid 100 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SOC + atorvastatin 80 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SOC + acetylsalicylic acid 100 mg daily + atorvastatin 8</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetylsalicylic acid</intervention_name>
    <description>100mg</description>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>80 mg</description>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the prostate and no curative local therapy&#xD;
             considered possible&#xD;
&#xD;
          -  Age ≥ 18 years, life expectancy of at least 6 months&#xD;
&#xD;
          -  CRPC defined as tumor progression (PSA increase on at least 2 separate values&#xD;
             separated by at least 1 week or progression on imaging) while on Androgen Deprivation&#xD;
             Therapy (orchiectomy, LHRH agonist or -antagonist) with documented serum testosterone&#xD;
             levels ≤ 1.7 nmol/L (≤ 0.50 ng/mL). Ongoing concurrent use of LHRH agonist or&#xD;
             antagonist is required if the patient has not been surgically castrated&#xD;
&#xD;
          -  Presence (M1) or absence (M0) of metastases on imaging&#xD;
&#xD;
          -  Performance status 0, 1 or 2&#xD;
&#xD;
          -  No previous use of life- prolonging treatments for CRPC (including abiraterone,&#xD;
             enzalutamide, radium-223, docetaxel, cabazitaxel, and sipuleucel-T). The use of these&#xD;
             agents together with Androgen Deprivation Therapy (ADT) for castrate-sensitive disease&#xD;
             is allowed.&#xD;
&#xD;
          -  Adequate renal function within 30 days prior to registration: calculated creatinine&#xD;
             clearance ≥ 50 mL/min, according to the formula of Cockcroft-Gault and adequate liver&#xD;
             function with levels of AST and ALT ≤ 3xULN and no signs for cholestasis.&#xD;
&#xD;
          -  Participation in other clinical trials is allowed except for trials with the same&#xD;
             primary endpoint, i.e. OS&#xD;
&#xD;
          -  Patient authorized to participate to a clinical trial by specific country regulation&#xD;
             (eg patient affiliated to a social security system or beneficiary of the same)&#xD;
&#xD;
          -  Information delivered to patient and informed consent form signed by the patient.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous localised malignancy within 2 years with the exception of localized&#xD;
             non-melanoma skin cancer and Ta or Tis bladder cancer (patients with asymptomatic&#xD;
             Chronic Lymphocytic Leukemia can be included)&#xD;
&#xD;
          -  Previous metastatic malignancy within 5 years&#xD;
&#xD;
          -  Patient currently taking daily acetylsalicylic acid or a daily statin within the last&#xD;
             6 months&#xD;
&#xD;
          -  Patients with active liver disease (hepatitis B or C, cirrhosis) or unexplained&#xD;
             persistent elevations of serum transaminases exceeding 3 times the upper limit of&#xD;
             normal or cholestasis&#xD;
&#xD;
          -  Patients with excessive alcohol intake or history of a relevant liver disease&#xD;
&#xD;
          -  Known hypersensitivity or intolerance to acetylsalicylic acid or atorvastatin or&#xD;
             hypersensitivity to any of its components&#xD;
&#xD;
          -  Contra-indication to acetylsalicylic acid or atorvastatin according to label,&#xD;
             including known high-risk for haemorrhage,&#xD;
&#xD;
          -  History of or active myopathy or significantly elevated (&gt; 5 times ULN) CK levels&#xD;
&#xD;
          -  History of recent stroke or transient ischemic attack (TIA).&#xD;
&#xD;
          -  Any concomitant drugs contraindicated for use with the trial drugs according to the&#xD;
             product information (e.g. Fusidic acid, potent inhibitors of CYP3A4 or transport&#xD;
             proteins: ciclosporin, telithromycin, clarithromycin, delavirdine, stiripentol,&#xD;
             ketoconazole, voriconazole, itraconazole, posaconazole and HIV protease inhibitors&#xD;
             including ritonavir, lopinavir, atazanavir, indinavir, darunavir, tipranavir,&#xD;
             telaprevir, saquinavir, darunavir, fosamprenavir, boceprevir, gemfibrozil,&#xD;
             fenofibrate, etc)&#xD;
&#xD;
          -  Any serious underlying medical condition (by the investigator's judgement) which could&#xD;
             impair the ability of the patient to participate in the trial&#xD;
&#xD;
          -  Patients with hereditary galactose intolerance, Lapp-lactase deficiency or&#xD;
             Glucose-Galactose-malabsorption&#xD;
&#xD;
          -  Compliance with trial medical follow-up impossible due to geographic, social or&#xD;
             psychological reasons&#xD;
&#xD;
          -  Psychiatric disorder precluding understanding of information about trial related&#xD;
             topics, providing informed consent, or interfering with compliance for oral drug&#xD;
             intake&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Prostate cancer</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Karim Fizazi, MD, PhD</last_name>
    <phone>0142114317</phone>
    <phone_ext>+33</phone_ext>
    <email>karim.fizazi@gustaveroussy.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gwenael Le Teuff</last_name>
    <phone>0142114955</phone>
    <phone_ext>+33</phone_ext>
    <email>gwenael.leteuff@gustaveroussy.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gustave Roussy Cancer Campus Grand Paris</name>
      <address>
        <city>Villejuif</city>
        <state>Val De Marne</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karim Fizazi, MD, PhD</last_name>
      <phone>0142114317</phone>
      <phone_ext>+33</phone_ext>
      <email>karim.fizazi@gustaveroussy.fr</email>
    </contact>
    <contact_backup>
      <last_name>Anne Sophie Hue</last_name>
      <phone>0142113890</phone>
      <phone_ext>+33</phone_ext>
      <email>anne-sophie.hue@gustaveroussy.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU Besançon Hopital Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine Thiery-Vuillemin, MD</last_name>
      <email>antoine.thieryvuillemin@oncologyfc2.onmicrosoft.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hakim Mahammedi, MD</last_name>
      <phone>04 73 27 81 41</phone>
      <email>Hakim.MAHAMMEDI@clermont.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé Sainte Marguerite</name>
      <address>
        <city>Hyères</city>
        <zip>83400</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-François Berdah, MD</last_name>
      <phone>04 94 12 55 60</phone>
      <email>jf.berdah@wanadoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Azuréen de Cancérologie</name>
      <address>
        <city>Mougins</city>
        <zip>06250</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Ronchin, MD</last_name>
      <phone>04 92 92 37 37</phone>
      <email>ronchinp@yahoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delphine Borchiellini, MD</last_name>
      <email>Delphine.BORCHIELLINI@nice.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Croix Saint Simon</name>
      <address>
        <city>Paris</city>
        <zip>75960</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Camille Serrate, MD</last_name>
      <email>cserrate@hopital-dcss.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Jean Godinot</name>
      <address>
        <city>Reims</city>
        <zip>51726</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Christophe Eymard, MD</last_name>
      <email>jc.eymard@reims.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital d'Instruction des Armées Bégin</name>
      <address>
        <city>Saint-Mandé</city>
        <zip>94160</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carole Helissey, MD</last_name>
      <phone>01 43 98 53 19</phone>
      <email>carolehelissey@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie Lucien Neuwirth</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42271</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aline Guillot, MD</last_name>
      <phone>04 77 97 70 34</phone>
      <email>aline.guillot@icloire.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yann Neuzillet, MD</last_name>
      <email>y.neuzillet@hopital-foch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Egea, MD</last_name>
      <email>j.egea@nancy.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik Hirslanden Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Baden</name>
      <address>
        <city>Baden</city>
        <zip>5404</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Bellinzona Istituto Oncologico</name>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Baselland</name>
      <address>
        <city>Bruderholz</city>
        <zip>4101</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Kantansspital Graubündern</name>
      <address>
        <city>Chur</city>
        <zip>7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Münsterlingen</name>
      <address>
        <city>Münsterlingen</city>
        <zip>8596</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St.Gallen</name>
      <address>
        <city>Saint Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stadtspital Triemli</name>
      <address>
        <city>Zürich</city>
        <zip>8063</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 24, 2019</study_first_submitted>
  <study_first_submitted_qc>January 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2019</study_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

